__label__noRel	In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).	Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.
__label__noRel	In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).	Headache, diarrhoea, and flushing were more common with sildenafil.
__label__Support	In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).	Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.
__label__noRel	Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.	In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).
__label__noRel	Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.	Headache, diarrhoea, and flushing were more common with sildenafil.
__label__Support	Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.	Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.
__label__noRel	Headache, diarrhoea, and flushing were more common with sildenafil.	In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).
__label__noRel	Headache, diarrhoea, and flushing were more common with sildenafil.	Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.
__label__noRel	Headache, diarrhoea, and flushing were more common with sildenafil.	Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.
__label__noRel	Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.	In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).
__label__noRel	Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.	Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.
__label__noRel	Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.	Headache, diarrhoea, and flushing were more common with sildenafil.
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__Support	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__noRel	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__Support	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__noRel	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__Support	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__noRel	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__noRel	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__noRel	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__Support	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__Support	No cases of drug-related neutropenic fever, sepsis, or death occurred.	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__noRel	No cases of drug-related neutropenic fever, sepsis, or death occurred.	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__Support	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__noRel	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	No cases of drug-related neutropenic fever, sepsis, or death occurred.
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.
__label__noRel	Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.	Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
__label__noRel	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).
__label__noRel	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).
__label__noRel	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.
__label__noRel	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.
__label__noRel	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.
__label__noRel	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.	No patients developed additional resistance mutations throughout the study period.
__label__Support	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.
__label__noRel	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).
__label__noRel	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.
__label__noRel	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.
__label__noRel	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.
__label__noRel	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).	No patients developed additional resistance mutations throughout the study period.
__label__Support	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.
__label__noRel	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).
__label__noRel	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.
__label__noRel	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.
__label__noRel	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.
__label__noRel	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).	No patients developed additional resistance mutations throughout the study period.
__label__noRel	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.
__label__noRel	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).
__label__noRel	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).
__label__noRel	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.
__label__noRel	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.
__label__noRel	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.	No patients developed additional resistance mutations throughout the study period.
__label__Support	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.
__label__noRel	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).
__label__noRel	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).
__label__noRel	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.
__label__noRel	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.
__label__noRel	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.	No patients developed additional resistance mutations throughout the study period.
__label__Support	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.
__label__noRel	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).
__label__noRel	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).
__label__noRel	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.
__label__noRel	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.
__label__noRel	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.	No patients developed additional resistance mutations throughout the study period.
__label__Support	No patients developed additional resistance mutations throughout the study period.	TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV.
__label__noRel	No patients developed additional resistance mutations throughout the study period.	Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).
__label__noRel	No patients developed additional resistance mutations throughout the study period.	At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).
__label__noRel	No patients developed additional resistance mutations throughout the study period.	By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.
__label__noRel	No patients developed additional resistance mutations throughout the study period.	Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.
__label__noRel	No patients developed additional resistance mutations throughout the study period.	At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.
__label__noRel	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,
__label__noRel	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).	but this result did not achieve statistical significance (P = 0.054).
__label__noRel	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).
__label__Support	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.
__label__noRel	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).
__label__noRel	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,	but this result did not achieve statistical significance (P = 0.054).
__label__noRel	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).
__label__noRel	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.
__label__noRel	but this result did not achieve statistical significance (P = 0.054).	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).
__label__Attack	but this result did not achieve statistical significance (P = 0.054).	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,
__label__noRel	but this result did not achieve statistical significance (P = 0.054).	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).
__label__noRel	but this result did not achieve statistical significance (P = 0.054).	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.
__label__noRel	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).
__label__noRel	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,
__label__noRel	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).	but this result did not achieve statistical significance (P = 0.054).
__label__Support	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.
__label__noRel	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.	In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P = 0.02), and 1.20% weight loss at 12 months (95% CI, 0.05-2.36%; P = 0.04).
__label__noRel	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.	At 12 months, there was a 0.30% (3.3 mmol/mol) reduction in hemoglobin A1c,
__label__noRel	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.	but this result did not achieve statistical significance (P = 0.054).
__label__noRel	Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12 months.	In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P = 0.02), and 2.07% weight loss at 12 months (95% CI, 0.25-3.88%; P = 0.02).
__label__noRel	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.
__label__noRel	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).
__label__noRel	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.
__label__noRel	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).
__label__noRel	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.
__label__noRel	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.
__label__Attack	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,
__label__noRel	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).
__label__noRel	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.
__label__noRel	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).
__label__noRel	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.
__label__noRel	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.
__label__noRel	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,
__label__noRel	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.
__label__noRel	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.
__label__noRel	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).
__label__Support	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.
__label__noRel	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.
__label__noRel	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,
__label__noRel	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.
__label__noRel	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).
__label__noRel	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).
__label__Support	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.
__label__noRel	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.
__label__noRel	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,
__label__noRel	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.
__label__noRel	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).
__label__noRel	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.
__label__Support	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.
__label__noRel	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.
__label__noRel	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,
__label__noRel	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.
__label__noRel	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).
__label__noRel	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.
__label__noRel	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).
__label__Support	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.
__label__noRel	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.	anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma,
__label__noRel	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.	adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.
__label__noRel	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.	Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p = 0.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25-4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006).
__label__noRel	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.	Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.
__label__noRel	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.	The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).
__label__noRel	Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.	Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__Support	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__noRel	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__Support	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__Support	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__Support	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	Drug-related toxicities were more frequent in the higher-dose group.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__Support	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	At 250 mg/d, gefitinib had a favorable AE profile.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).
__label__noRel	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).
__label__noRel	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).
__label__noRel	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).
__label__noRel	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.
__label__noRel	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.
__label__noRel	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).
__label__noRel	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).
__label__noRel	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).
__label__Support	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.
__label__noRel	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.
__label__noRel	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).
__label__noRel	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).
__label__noRel	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).
__label__Support	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.
__label__noRel	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.
__label__Support	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).
__label__noRel	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).
__label__noRel	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).
__label__noRel	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.
__label__noRel	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.
__label__noRel	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).
__label__noRel	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).
__label__noRel	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).
__label__Support	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.
__label__Support	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.	The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices.
__label__noRel	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.	After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5±7.7 vs. 82.4±13.5 μmol/L); International Normalized Ratio (INR) (1.21±0.8 vs. 1.14±0.7); creatinine (147.3±12.4 vs. 287.4±21.6 mg/dL); GGT (67.4±23.2 vs. 88.4±23.7 U/L); and ALT (63.4±40.8 vs. 96.5±23.5 U/L).
__label__noRel	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.	In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5±7.7 vs. 82.4±13.5 μg/L); IV-C (61.3±18.7 vs. 74.5±17.9 μg/L); HA (147.3±12.4 vs. 87.4±31.6 μg/L); and LN (88.7±13.2 vs 102.5±23.4 μg/L).
__label__noRel	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.	The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).
__label__noRel	In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.	After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7±3.2 vs. 22.5±3.4), with a statistically significant difference (P<0.05).
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.	because neorectal capacity decreased equally in both groups,
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.	because neorectal capacity decreased equally in both groups,
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__Support	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.	because neorectal capacity decreased equally in both groups,
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__Support	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).	because neorectal capacity decreased equally in both groups,
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__Support	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.	because neorectal capacity decreased equally in both groups,
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__Support	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.	because neorectal capacity decreased equally in both groups,
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.	because neorectal capacity decreased equally in both groups,
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.	because neorectal capacity decreased equally in both groups,
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__noRel	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	because neorectal capacity decreased equally in both groups,
__label__noRel	because neorectal capacity decreased equally in both groups,	Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
__label__noRel	because neorectal capacity decreased equally in both groups,	However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.
__label__noRel	because neorectal capacity decreased equally in both groups,	problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
__label__noRel	because neorectal capacity decreased equally in both groups,	The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
__label__noRel	because neorectal capacity decreased equally in both groups,	in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.
__label__noRel	because neorectal capacity decreased equally in both groups,	the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
__label__noRel	because neorectal capacity decreased equally in both groups,	The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
__label__noRel	because neorectal capacity decreased equally in both groups,	stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
__label__Support	because neorectal capacity decreased equally in both groups,	we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
__label__noRel	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.
__label__noRel	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.
__label__noRel	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).
__label__noRel	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.
__label__Support	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.
__label__noRel	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).
__label__noRel	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.
__label__noRel	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.
__label__noRel	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).
__label__noRel	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.
__label__noRel	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.
__label__Support	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.
__label__noRel	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).
__label__noRel	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.
__label__noRel	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.
__label__noRel	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.	The incidence of hepatotoxicity during IPT and ART was high.
__label__noRel	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.
__label__noRel	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.
__label__noRel	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.
__label__Support	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).	The incidence of hepatotoxicity during IPT and ART was high.
__label__noRel	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.
__label__noRel	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).
__label__noRel	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.
__label__Support	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.	The incidence of hepatotoxicity during IPT and ART was high.
__label__noRel	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.
__label__noRel	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).
__label__noRel	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.
__label__Support	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.	The incidence of hepatotoxicity during IPT and ART was high.
__label__noRel	The incidence of hepatotoxicity during IPT and ART was high.	Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity.
__label__noRel	The incidence of hepatotoxicity during IPT and ART was high.	Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/µL), 31 developed hepatotoxicity (7.3%).
__label__noRel	The incidence of hepatotoxicity during IPT and ART was high.	Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.
__label__noRel	The incidence of hepatotoxicity during IPT and ART was high.	Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.
__label__noRel	Synbiotic is effective in reducing of blood pressure in women with GDM.	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).
__label__noRel	Synbiotic is effective in reducing of blood pressure in women with GDM.	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).
__label__noRel	Synbiotic is effective in reducing of blood pressure in women with GDM.	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).
__label__noRel	Synbiotic is effective in reducing of blood pressure in women with GDM.	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).
__label__noRel	Synbiotic is effective in reducing of blood pressure in women with GDM.	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.
__label__noRel	Synbiotic is effective in reducing of blood pressure in women with GDM.	Lipid profile and TAC status may be affected by synbiotic supplementation.
__label__noRel	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).	Synbiotic is effective in reducing of blood pressure in women with GDM.
__label__noRel	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).
__label__noRel	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).
__label__noRel	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).
__label__Support	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.
__label__noRel	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).	Lipid profile and TAC status may be affected by synbiotic supplementation.
__label__noRel	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).	Synbiotic is effective in reducing of blood pressure in women with GDM.
__label__noRel	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).
__label__noRel	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).
__label__noRel	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).
__label__noRel	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.
__label__Support	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).	Lipid profile and TAC status may be affected by synbiotic supplementation.
__label__noRel	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).	Synbiotic is effective in reducing of blood pressure in women with GDM.
__label__noRel	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).
__label__noRel	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).
__label__noRel	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).
__label__noRel	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.
__label__Support	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).	Lipid profile and TAC status may be affected by synbiotic supplementation.
__label__Support	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).	Synbiotic is effective in reducing of blood pressure in women with GDM.
__label__noRel	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).
__label__noRel	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).
__label__noRel	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).
__label__noRel	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.
__label__noRel	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).	Lipid profile and TAC status may be affected by synbiotic supplementation.
__label__noRel	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.	Synbiotic is effective in reducing of blood pressure in women with GDM.
__label__noRel	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).
__label__noRel	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).
__label__noRel	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).
__label__noRel	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).
__label__noRel	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.	Lipid profile and TAC status may be affected by synbiotic supplementation.
__label__noRel	Lipid profile and TAC status may be affected by synbiotic supplementation.	Synbiotic is effective in reducing of blood pressure in women with GDM.
__label__noRel	Lipid profile and TAC status may be affected by synbiotic supplementation.	No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p > 0.05).
__label__noRel	Lipid profile and TAC status may be affected by synbiotic supplementation.	Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p < 0.05).
__label__noRel	Lipid profile and TAC status may be affected by synbiotic supplementation.	LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9 mg/dL, p < 0.05).
__label__noRel	Lipid profile and TAC status may be affected by synbiotic supplementation.	Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6 mmHg, and -1.8 vs. 2.1 mmHg, p < 0.05).
__label__noRel	Lipid profile and TAC status may be affected by synbiotic supplementation.	The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__Support	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__Support	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__Support	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).
__label__noRel	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).
__label__noRel	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.
__label__Support	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.
__label__noRel	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).
__label__noRel	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.
__label__noRel	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.
__label__noRel	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).
__label__noRel	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.
__label__noRel	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.
__label__noRel	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).
__label__noRel	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).
__label__noRel	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.	At 1 year, the mean postoperative IOP was significantly lower in group A.
__label__noRel	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.
__label__noRel	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.
__label__Support	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.
__label__noRel	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.	Our results suggest that ologen may be a useful alternative to MMC in JOAG.
__label__noRel	At 1 year, the mean postoperative IOP was significantly lower in group A.	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.
__label__noRel	At 1 year, the mean postoperative IOP was significantly lower in group A.	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.
__label__noRel	At 1 year, the mean postoperative IOP was significantly lower in group A.	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.
__label__Support	At 1 year, the mean postoperative IOP was significantly lower in group A.	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.
__label__noRel	At 1 year, the mean postoperative IOP was significantly lower in group A.	Our results suggest that ologen may be a useful alternative to MMC in JOAG.
__label__noRel	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.
__label__noRel	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.	At 1 year, the mean postoperative IOP was significantly lower in group A.
__label__noRel	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.
__label__Support	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.
__label__noRel	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.	Our results suggest that ologen may be a useful alternative to MMC in JOAG.
__label__noRel	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.
__label__noRel	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.	At 1 year, the mean postoperative IOP was significantly lower in group A.
__label__noRel	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.
__label__Support	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.
__label__noRel	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.	Our results suggest that ologen may be a useful alternative to MMC in JOAG.
__label__noRel	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.
__label__noRel	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.	At 1 year, the mean postoperative IOP was significantly lower in group A.
__label__noRel	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.
__label__noRel	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.
__label__Support	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.	Our results suggest that ologen may be a useful alternative to MMC in JOAG.
__label__noRel	Our results suggest that ologen may be a useful alternative to MMC in JOAG.	The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.
__label__noRel	Our results suggest that ologen may be a useful alternative to MMC in JOAG.	At 1 year, the mean postoperative IOP was significantly lower in group A.
__label__noRel	Our results suggest that ologen may be a useful alternative to MMC in JOAG.	According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.
__label__noRel	Our results suggest that ologen may be a useful alternative to MMC in JOAG.	AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.
__label__noRel	Our results suggest that ologen may be a useful alternative to MMC in JOAG.	Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__Support	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__Support	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__Support	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__Support	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).	Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT.
__label__Support	In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).	Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.
__label__noRel	In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).	changing medication from PT to NPT might improve subjective satisfaction and tear break up time.
__label__noRel	Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT.	In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).
__label__noRel	Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT.	Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.
__label__noRel	Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT.	changing medication from PT to NPT might improve subjective satisfaction and tear break up time.
__label__noRel	Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.	In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).
__label__noRel	Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.	Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT.
__label__noRel	Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.	changing medication from PT to NPT might improve subjective satisfaction and tear break up time.
__label__noRel	changing medication from PT to NPT might improve subjective satisfaction and tear break up time.	In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).
__label__noRel	changing medication from PT to NPT might improve subjective satisfaction and tear break up time.	Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT.
__label__noRel	changing medication from PT to NPT might improve subjective satisfaction and tear break up time.	Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.
__label__noRel	There was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.	Appropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters.
__label__noRel	Appropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters.	There was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__noRel	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__Support	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__Support	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__Support	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__Support	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__Support	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__Support	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__Support	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__Support	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__noRel	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__noRel	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__Support	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__noRel	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__noRel	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__noRel	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__Support	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__noRel	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__noRel	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__noRel	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__noRel	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__noRel	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
__label__noRel	Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.	GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.
__label__Support	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).	Both procedures produced a statistically significant reduction in IOP,
__label__noRel	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).
__label__noRel	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.
__label__noRel	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.
__label__noRel	Both procedures produced a statistically significant reduction in IOP,	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).
__label__noRel	Both procedures produced a statistically significant reduction in IOP,	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).
__label__noRel	Both procedures produced a statistically significant reduction in IOP,	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.
__label__noRel	Both procedures produced a statistically significant reduction in IOP,	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.
__label__noRel	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).
__label__Support	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).	Both procedures produced a statistically significant reduction in IOP,
__label__noRel	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.
__label__noRel	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.
__label__noRel	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).
__label__noRel	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.	Both procedures produced a statistically significant reduction in IOP,
__label__noRel	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).
__label__noRel	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.
__label__noRel	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.	For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).
__label__noRel	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.	Both procedures produced a statistically significant reduction in IOP,
__label__noRel	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.	eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 ± 2.4 mm Hg and 11.7 ± 2.1 mm Hg, respectively, P < .001).
__label__noRel	In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.	In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements.
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	No TDF resistance was observed up to week 240.
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	No TDF resistance was observed up to week 240.
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	No TDF resistance was observed up to week 240.
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	No TDF resistance was observed up to week 240.
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__Support	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	No TDF resistance was observed up to week 240.
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__Support	No TDF resistance was observed up to week 240.	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	No TDF resistance was observed up to week 240.	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	No TDF resistance was observed up to week 240.	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	No TDF resistance was observed up to week 240.	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	No TDF resistance was observed up to week 240.	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	No TDF resistance was observed up to week 240.	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	No TDF resistance was observed up to week 240.	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	No TDF resistance was observed up to week 240.	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__Support	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	No TDF resistance was observed up to week 240.
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	No TDF resistance was observed up to week 240.
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	No TDF resistance was observed up to week 240.
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%).
__label__noRel	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
__label__noRel	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).
__label__noRel	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).
__label__Support	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;
__label__noRel	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).	however, it increases the risk of early filtering bleb leakage.
__label__noRel	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).
__label__noRel	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).
__label__noRel	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).
__label__noRel	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).
__label__Support	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;
__label__noRel	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	however, it increases the risk of early filtering bleb leakage.
__label__noRel	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).
__label__noRel	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).
__label__noRel	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).
__label__noRel	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).
__label__Support	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;
__label__noRel	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).	however, it increases the risk of early filtering bleb leakage.
__label__noRel	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).
__label__noRel	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).
__label__noRel	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).
__label__noRel	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).
__label__noRel	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).
__label__noRel	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;	however, it increases the risk of early filtering bleb leakage.
__label__noRel	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).
__label__noRel	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).
__label__noRel	however, it increases the risk of early filtering bleb leakage.	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).
__label__noRel	however, it increases the risk of early filtering bleb leakage.	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).
__label__noRel	however, it increases the risk of early filtering bleb leakage.	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).
__label__Attack	however, it increases the risk of early filtering bleb leakage.	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;
__label__noRel	however, it increases the risk of early filtering bleb leakage.	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).
__label__noRel	however, it increases the risk of early filtering bleb leakage.	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).
__label__noRel	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).
__label__noRel	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).
__label__noRel	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).
__label__noRel	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;
__label__noRel	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).	however, it increases the risk of early filtering bleb leakage.
__label__noRel	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).
__label__noRel	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).	Compared with baseline, IOP drop at last visit was 11.76±5.51 and 13.43±5.92 in the bevacizumab and MMC groups, respectively (P=0.207).
__label__noRel	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).	At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).
__label__noRel	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).	Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).
__label__noRel	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).	A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC;
__label__noRel	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).	however, it increases the risk of early filtering bleb leakage.
__label__noRel	Last visit IOP was 17.41±3.11 mm Hg in the bevacizumab group and 15.34±3.62 mm Hg in the MMC group (P<0.009).	The preoperative IOP was 29.17±3.94 and 28.8±4.08 mm Hg in the bevacizumab and MMC groups, respectively (P=0.689).
__label__noRel	Treatment-related quality of life (QOL) is an important aspect of diabetes management.	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.
__label__noRel	Treatment-related quality of life (QOL) is an important aspect of diabetes management.	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.
__label__noRel	Treatment-related quality of life (QOL) is an important aspect of diabetes management.	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.
__label__noRel	Treatment-related quality of life (QOL) is an important aspect of diabetes management.	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.
__label__noRel	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.	Treatment-related quality of life (QOL) is an important aspect of diabetes management.
__label__noRel	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.
__label__noRel	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.
__label__noRel	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.
__label__noRel	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.	Treatment-related quality of life (QOL) is an important aspect of diabetes management.
__label__noRel	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.
__label__noRel	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.
__label__Support	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.
__label__noRel	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.	Treatment-related quality of life (QOL) is an important aspect of diabetes management.
__label__noRel	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.
__label__noRel	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.
__label__Support	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.
__label__noRel	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.	Treatment-related quality of life (QOL) is an important aspect of diabetes management.
__label__noRel	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.	Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.
__label__noRel	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.	The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.
__label__noRel	Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.	In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.
__label__noRel	At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).	A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).
__label__noRel	At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).	In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).
__label__Support	At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).	Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.
__label__noRel	A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).	At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).
__label__noRel	A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).	In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).
__label__Support	A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).	Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.
__label__noRel	In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).	At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).
__label__noRel	In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).	A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).
__label__noRel	In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).	Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.
__label__noRel	Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.	At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).
__label__noRel	Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.	A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).
__label__noRel	Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists.	In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	the survival rates were by-and-large the same for the two groups.
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	the survival rates were by-and-large the same for the two groups.
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	the survival rates were by-and-large the same for the two groups.	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	the survival rates were by-and-large the same for the two groups.	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__noRel	the survival rates were by-and-large the same for the two groups.	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__Support	the survival rates were by-and-large the same for the two groups.	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__noRel	the survival rates were by-and-large the same for the two groups.	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	the survival rates were by-and-large the same for the two groups.	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	the survival rates were by-and-large the same for the two groups.	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__noRel	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	the survival rates were by-and-large the same for the two groups.
__label__noRel	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__Support	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	the survival rates were by-and-large the same for the two groups.
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	the survival rates were by-and-large the same for the two groups.
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__Support	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	the survival rates were by-and-large the same for the two groups.
__label__noRel	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__noRel	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__noRel	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
__label__noRel	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.
__label__noRel	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
__label__Support	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	the survival rates were by-and-large the same for the two groups.
__label__noRel	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.
__label__noRel	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
__label__noRel	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.
__label__noRel	A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).	After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__Support	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__Support	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__Support	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__Support	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.
__label__noRel	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).
__label__noRel	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.
__label__noRel	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension
__label__noRel	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).
__label__Support	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.
__label__noRel	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension
__label__noRel	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.
__label__Support	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.
__label__Attack	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension
__label__noRel	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.
__label__noRel	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	The patient accrual of our trial is satisfactory,
__label__noRel	In recent years, encouraging results of preoperative radiotherapy have been reported.	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	The patient accrual of our trial is satisfactory,
__label__noRel	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	The patient accrual of our trial is satisfactory,
__label__Support	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	The patient accrual of our trial is satisfactory,
__label__Support	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	The patient accrual of our trial is satisfactory,
__label__Support	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	The patient accrual of our trial is satisfactory,
__label__Support	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	The patient accrual of our trial is satisfactory,	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	The patient accrual of our trial is satisfactory,	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	The patient accrual of our trial is satisfactory,	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	The patient accrual of our trial is satisfactory,	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	The patient accrual of our trial is satisfactory,	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	The patient accrual of our trial is satisfactory,	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	The patient accrual of our trial is satisfactory,	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	In recent years, encouraging results of preoperative radiotherapy have been reported.
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.
__label__noRel	neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.	The patient accrual of our trial is satisfactory,
__label__noRel	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).
__label__noRel	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).
__label__noRel	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).
__label__noRel	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.
__label__noRel	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.
__label__noRel	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).
__label__noRel	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).
__label__Support	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.
__label__noRel	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.
__label__noRel	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).
__label__noRel	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).
__label__noRel	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.
__label__noRel	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.
__label__noRel	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).
__label__noRel	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).
__label__Support	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.
__label__noRel	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.	Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.
__label__noRel	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.	Eight weeks supplementation with EPA led to significant reductions in Met (p < 0.002) and Cys (p < 0.001) compared with the placebo (p < 0.06).
__label__noRel	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.	Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).
__label__noRel	EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients.	compared to placebo a significant reduction in AIP were seen after taking EPA (p < 0.04).
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	but evidence from trials is inconclusive.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__Attack	but evidence from trials is inconclusive.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	but evidence from trials is inconclusive.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	but evidence from trials is inconclusive.	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	but evidence from trials is inconclusive.	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	but evidence from trials is inconclusive.	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	but evidence from trials is inconclusive.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	but evidence from trials is inconclusive.
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__Support	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	but evidence from trials is inconclusive.
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	but evidence from trials is inconclusive.
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__noRel	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__Support	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__Support	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__Support	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).
__label__noRel	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.	The data offered support to the null hypothesis and therefore research hypothesis was rejected.
__label__noRel	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).
__label__noRel	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.
__label__noRel	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.	The efficacy response is equal in both drugs while test drug showed more safety response.
__label__noRel	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.
__label__noRel	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).	The data offered support to the null hypothesis and therefore research hypothesis was rejected.
__label__noRel	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).
__label__noRel	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.
__label__Support	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).	The efficacy response is equal in both drugs while test drug showed more safety response.
__label__noRel	The data offered support to the null hypothesis and therefore research hypothesis was rejected.	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.
__label__noRel	The data offered support to the null hypothesis and therefore research hypothesis was rejected.	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).
__label__noRel	The data offered support to the null hypothesis and therefore research hypothesis was rejected.	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).
__label__noRel	The data offered support to the null hypothesis and therefore research hypothesis was rejected.	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.
__label__noRel	The data offered support to the null hypothesis and therefore research hypothesis was rejected.	The efficacy response is equal in both drugs while test drug showed more safety response.
__label__noRel	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.
__label__noRel	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).
__label__noRel	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).	The data offered support to the null hypothesis and therefore research hypothesis was rejected.
__label__noRel	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.
__label__Support	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).	The efficacy response is equal in both drugs while test drug showed more safety response.
__label__noRel	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.
__label__noRel	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).
__label__noRel	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.	The data offered support to the null hypothesis and therefore research hypothesis was rejected.
__label__noRel	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).
__label__Support	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.	The efficacy response is equal in both drugs while test drug showed more safety response.
__label__Support	The efficacy response is equal in both drugs while test drug showed more safety response.	It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine.
__label__noRel	The efficacy response is equal in both drugs while test drug showed more safety response.	No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).
__label__noRel	The efficacy response is equal in both drugs while test drug showed more safety response.	The data offered support to the null hypothesis and therefore research hypothesis was rejected.
__label__noRel	The efficacy response is equal in both drugs while test drug showed more safety response.	According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).
__label__noRel	The efficacy response is equal in both drugs while test drug showed more safety response.	Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	no changes in peripheral glucose disposal were observed.
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	no changes in peripheral glucose disposal were observed.
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	no changes in peripheral glucose disposal were observed.
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__Support	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	no changes in peripheral glucose disposal were observed.
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	no changes in peripheral glucose disposal were observed.	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	no changes in peripheral glucose disposal were observed.	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__noRel	no changes in peripheral glucose disposal were observed.	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	no changes in peripheral glucose disposal were observed.	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	no changes in peripheral glucose disposal were observed.	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	no changes in peripheral glucose disposal were observed.	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	no changes in peripheral glucose disposal were observed.	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	no changes in peripheral glucose disposal were observed.	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	no changes in peripheral glucose disposal were observed.
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	no changes in peripheral glucose disposal were observed.
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__Support	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	no changes in peripheral glucose disposal were observed.
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance.
__label__Support	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015),
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	no changes in peripheral glucose disposal were observed.
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002),
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups.
__label__noRel	We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx.	DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006).
__label__noRel	Hypertension is a generally accepted atherogenic risk factor.	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).
__label__noRel	Hypertension is a generally accepted atherogenic risk factor.	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .
__label__noRel	Hypertension is a generally accepted atherogenic risk factor.	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.
__label__noRel	Hypertension is a generally accepted atherogenic risk factor.	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.
__label__noRel	Hypertension is a generally accepted atherogenic risk factor.	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.
__label__noRel	Hypertension is a generally accepted atherogenic risk factor.	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.
__label__noRel	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).	Hypertension is a generally accepted atherogenic risk factor.
__label__noRel	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .
__label__noRel	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.
__label__noRel	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.
__label__Support	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.
__label__noRel	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.
__label__noRel	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .	Hypertension is a generally accepted atherogenic risk factor.
__label__noRel	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).
__label__noRel	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.
__label__noRel	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.
__label__Support	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.
__label__noRel	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.
__label__noRel	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.	Hypertension is a generally accepted atherogenic risk factor.
__label__noRel	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).
__label__noRel	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .
__label__noRel	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.
__label__noRel	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.
__label__noRel	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.
__label__noRel	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.	Hypertension is a generally accepted atherogenic risk factor.
__label__noRel	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).
__label__noRel	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .
__label__noRel	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.
__label__noRel	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.
__label__noRel	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.
__label__noRel	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.	Hypertension is a generally accepted atherogenic risk factor.
__label__noRel	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).
__label__noRel	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .
__label__noRel	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.
__label__noRel	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.
__label__noRel	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.
__label__noRel	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.	Hypertension is a generally accepted atherogenic risk factor.
__label__noRel	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.	The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 ± 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 ± 2.74, p < 0.01) and total cholesterol (6.97 ± 1.08, p < 0.001).
__label__noRel	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.	Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .
__label__noRel	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.	In a full-model logistic regression, significant risk factors for an increase in IMT of ≥1.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.
__label__noRel	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.	The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.
__label__noRel	By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension.	Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.
__label__Attack	Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.	Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.
__label__noRel	Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.	RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).
__label__noRel	Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.	A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).
__label__noRel	Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.	Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.
__label__noRel	Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.	RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).
__label__noRel	Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.	A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).
__label__noRel	RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).	Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.
__label__Support	RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).	Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.
__label__noRel	RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).	A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).
__label__noRel	A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).	Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus.
__label__Support	A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).	Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.
__label__noRel	A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).	RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).
__label__noRel	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.
__label__noRel	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).
__label__noRel	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;
__label__noRel	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.
__label__noRel	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.
__label__Support	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.
__label__noRel	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).
__label__noRel	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;
__label__noRel	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.
__label__noRel	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.
__label__noRel	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.
__label__noRel	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.
__label__noRel	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;
__label__noRel	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.
__label__noRel	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.
__label__Support	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.
__label__noRel	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.
__label__noRel	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).
__label__noRel	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.
__label__noRel	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.
__label__Support	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.
__label__noRel	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.
__label__noRel	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).
__label__noRel	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;
__label__noRel	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.
__label__noRel	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.	Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms.
__label__noRel	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.	Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity.
__label__noRel	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.	No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).
__label__noRel	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.	ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels;
__label__noRel	Multivariate analyses showed that ≥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.	no patient demonstrated significant serum interferon alpha (IFNα) expression at any timepoint evaluated.
__label__noRel	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).
__label__noRel	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);
__label__noRel	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
__label__Support	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.
__label__noRel	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.
__label__noRel	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);
__label__noRel	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
__label__noRel	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.
__label__noRel	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.
__label__noRel	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).
__label__noRel	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
__label__Support	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.
__label__noRel	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.
__label__noRel	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).
__label__noRel	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);
__label__noRel	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.
__label__noRel	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.	Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.
__label__noRel	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.	The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).
__label__noRel	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.	After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);
__label__noRel	Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.	this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
__label__noRel	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__noRel	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__Support	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__noRel	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__Support	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__Support	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__Support	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__noRel	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
__label__noRel	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
__label__noRel	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.	However, the difference among these three groups and the 24-week optimized therapy group were significant.
__label__noRel	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.	Differences were not observed in the HBeAg seroconversion between each group.
__label__noRel	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
__label__noRel	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
__label__noRel	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
__label__noRel	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
__label__noRel	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.	However, the difference among these three groups and the 24-week optimized therapy group were significant.
__label__noRel	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.	Differences were not observed in the HBeAg seroconversion between each group.
__label__noRel	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
__label__noRel	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
__label__noRel	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
__label__noRel	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
__label__noRel	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.	However, the difference among these three groups and the 24-week optimized therapy group were significant.
__label__noRel	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.	Differences were not observed in the HBeAg seroconversion between each group.
__label__noRel	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
__label__noRel	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
__label__Support	However, the difference among these three groups and the 24-week optimized therapy group were significant.	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
__label__noRel	However, the difference among these three groups and the 24-week optimized therapy group were significant.	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
__label__noRel	However, the difference among these three groups and the 24-week optimized therapy group were significant.	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
__label__noRel	However, the difference among these three groups and the 24-week optimized therapy group were significant.	Differences were not observed in the HBeAg seroconversion between each group.
__label__noRel	However, the difference among these three groups and the 24-week optimized therapy group were significant.	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
__label__noRel	However, the difference among these three groups and the 24-week optimized therapy group were significant.	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
__label__noRel	Differences were not observed in the HBeAg seroconversion between each group.	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
__label__noRel	Differences were not observed in the HBeAg seroconversion between each group.	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
__label__noRel	Differences were not observed in the HBeAg seroconversion between each group.	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
__label__noRel	Differences were not observed in the HBeAg seroconversion between each group.	However, the difference among these three groups and the 24-week optimized therapy group were significant.
__label__noRel	Differences were not observed in the HBeAg seroconversion between each group.	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
__label__noRel	Differences were not observed in the HBeAg seroconversion between each group.	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
__label__noRel	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
__label__noRel	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
__label__noRel	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
__label__noRel	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.	However, the difference among these three groups and the 24-week optimized therapy group were significant.
__label__noRel	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.	Differences were not observed in the HBeAg seroconversion between each group.
__label__noRel	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.
__label__noRel	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.	There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.
__label__noRel	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.	For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.
__label__noRel	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.	At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.
__label__noRel	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.	However, the difference among these three groups and the 24-week optimized therapy group were significant.
__label__noRel	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.	Differences were not observed in the HBeAg seroconversion between each group.
__label__noRel	Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis.	Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Support	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Support	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Attack	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Support	no difference was observed after the second week (P=0.659 to 0.753).	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).
__label__noRel	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).
__label__noRel	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).	Treatment-related adverse events or serious adverse events were uncommon.
__label__Support	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.
__label__noRel	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).
__label__noRel	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).
__label__noRel	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).	Treatment-related adverse events or serious adverse events were uncommon.
__label__Support	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.
__label__noRel	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).
__label__noRel	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).
__label__noRel	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).	Treatment-related adverse events or serious adverse events were uncommon.
__label__Support	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.
__label__noRel	Treatment-related adverse events or serious adverse events were uncommon.	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).
__label__noRel	Treatment-related adverse events or serious adverse events were uncommon.	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).
__label__noRel	Treatment-related adverse events or serious adverse events were uncommon.	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).
__label__noRel	Treatment-related adverse events or serious adverse events were uncommon.	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.
__label__noRel	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.	Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).
__label__noRel	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.	At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).
__label__noRel	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.	LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).
__label__noRel	Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients.	Treatment-related adverse events or serious adverse events were uncommon.
__label__noRel	Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).	Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).
__label__Support	Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).	Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.
__label__noRel	Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).	Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.
__label__noRel	Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).	Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).
__label__Support	Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).	Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.
__label__noRel	Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).	Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.
__label__noRel	Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.	Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).
__label__noRel	Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.	Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).
__label__noRel	Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.	Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.
__label__noRel	Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.	Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).
__label__noRel	Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.	Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 ± 3.40 mmHg increase in HFHT group vs 1.55 ± 2.59 mmHg increase in LFLT group, p = 0.0008).
__label__noRel	Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE.	Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.
__label__noRel	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
__label__noRel	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).
__label__noRel	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
__label__noRel	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.
__label__Support	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
__label__noRel	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
__label__noRel	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).
__label__noRel	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
__label__noRel	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.
__label__noRel	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
__label__noRel	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
__label__noRel	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
__label__noRel	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
__label__noRel	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.
__label__noRel	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
__label__noRel	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
__label__noRel	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
__label__noRel	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).
__label__noRel	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.
__label__Support	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
__label__noRel	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
__label__noRel	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
__label__noRel	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).
__label__noRel	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
__label__noRel	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
__label__noRel	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.	The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
__label__noRel	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.	All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
__label__noRel	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.	Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).
__label__noRel	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.	DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
__label__noRel	DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.	The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.
__label__noRel	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.
__label__noRel	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).
__label__noRel	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.
__label__Support	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.
__label__noRel	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).
__label__noRel	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.
__label__noRel	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.
__label__Support	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.
__label__noRel	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.
__label__noRel	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.
__label__Support	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.
__label__noRel	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).
__label__noRel	Both drops provided effective IOP reduction that was greater	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	Both drops provided effective IOP reduction that was greater	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Both drops provided effective IOP reduction that was greater	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	Both drops provided effective IOP reduction that was greater	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	Both drops provided effective IOP reduction that was greater	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	Both drops provided effective IOP reduction that was greater
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__Support	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Both drops provided effective IOP reduction that was greater
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	Both drops provided effective IOP reduction that was greater
__label__Support	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__Support	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	Both drops provided effective IOP reduction that was greater
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__Support	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	Both drops provided effective IOP reduction that was greater
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.
__label__noRel	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.
__label__noRel	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).	Safety was comparable among treatment groups.
__label__Support	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
__label__noRel	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
__label__noRel	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.
__label__noRel	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.	Safety was comparable among treatment groups.
__label__Attack	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
__label__noRel	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
__label__noRel	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.
__label__noRel	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.	Safety was comparable among treatment groups.
__label__noRel	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
__label__noRel	Safety was comparable among treatment groups.	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
__label__noRel	Safety was comparable among treatment groups.	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.
__label__noRel	Safety was comparable among treatment groups.	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.
__label__Support	Safety was comparable among treatment groups.	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
__label__noRel	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.	No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
__label__noRel	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.	However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.
__label__noRel	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.	Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.
__label__noRel	Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.	Safety was comparable among treatment groups.
__label__noRel	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__noRel	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__noRel	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__Support	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.	These two treatments are always superior to CAP.
__label__noRel	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__noRel	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__noRel	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__Support	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	These two treatments are always superior to CAP.
__label__noRel	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__Support	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__noRel	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.	These two treatments are always superior to CAP.
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__noRel	Fludarabine was consistently a better treatment than ChOP,	These two treatments are always superior to CAP.
__label__noRel	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__Attack	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__noRel	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__noRel	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.	These two treatments are always superior to CAP.
__label__noRel	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__Support	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__noRel	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).	These two treatments are always superior to CAP.
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__noRel	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.	These two treatments are always superior to CAP.
__label__noRel	These two treatments are always superior to CAP.	Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.
__label__noRel	These two treatments are always superior to CAP.	The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.
__label__noRel	These two treatments are always superior to CAP.	The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.
__label__noRel	These two treatments are always superior to CAP.	Fludarabine was consistently a better treatment than ChOP,
__label__noRel	These two treatments are always superior to CAP.	except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
__label__noRel	These two treatments are always superior to CAP.	from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).
__label__noRel	These two treatments are always superior to CAP.	patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__Support	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__Support	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__Support	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__Support	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__noRel	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__noRel	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.	but resulted in greater toxicity and inferior quality of life.
__label__noRel	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__Support	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__noRel	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__noRel	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.	but resulted in greater toxicity and inferior quality of life.
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__noRel	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.	but resulted in greater toxicity and inferior quality of life.
__label__noRel	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__noRel	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__Support	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.	but resulted in greater toxicity and inferior quality of life.
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__noRel	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.	but resulted in greater toxicity and inferior quality of life.
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__noRel	The Lokich regimen was associated with more central line complications and hand-foot syndrome.	but resulted in greater toxicity and inferior quality of life.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__noRel	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,	but resulted in greater toxicity and inferior quality of life.
__label__noRel	but resulted in greater toxicity and inferior quality of life.	The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.
__label__noRel	but resulted in greater toxicity and inferior quality of life.	For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.
__label__noRel	but resulted in greater toxicity and inferior quality of life.	An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.
__label__noRel	but resulted in greater toxicity and inferior quality of life.	Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.
__label__noRel	but resulted in greater toxicity and inferior quality of life.	The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.
__label__noRel	but resulted in greater toxicity and inferior quality of life.	The Lokich regimen was associated with more central line complications and hand-foot syndrome.
__label__Attack	but resulted in greater toxicity and inferior quality of life.	Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,
__label__noRel	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).
__label__noRel	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.
__label__Support	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.
__label__noRel	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).
__label__noRel	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.
__label__noRel	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.
__label__Support	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.
__label__noRel	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).
__label__noRel	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.
__label__noRel	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).
__label__noRel	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.
__label__noRel	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).
__label__noRel	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.
__label__noRel	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).
__label__noRel	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.
__label__noRel	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).
__label__noRel	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).	The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.
__label__noRel	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).	Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63).
__label__noRel	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).	No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.
__label__noRel	The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).	Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.
__label__noRel	At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.	Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).
__label__Support	At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.	The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.
__label__noRel	Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).	At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.
__label__Support	Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).	The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.
__label__noRel	The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.	At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, η2 p = 0.014.
__label__noRel	The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function.	Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: β = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: β = 0.69; 95% CI 0.06 to 1.32, p = 0.033).
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__Support	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__Support	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__Attack	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__Support	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__Support	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Aldosterone blood levels did not change.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__Support	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Aldosterone blood levels did not change.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Aldosterone blood levels did not change.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Diastolic blood pressure did not change during the sessions.
__label__Support	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Aldosterone blood levels did not change.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Aldosterone blood levels did not change.
__label__noRel	Aldosterone blood levels did not change.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Aldosterone blood levels did not change.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Aldosterone blood levels did not change.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Aldosterone blood levels did not change.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__noRel	Aldosterone blood levels did not change.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Support	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Attack	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Support	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Support	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	but have not shown beneficial effects on eGFR.
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__Support	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__Attack	but have not shown beneficial effects on eGFR.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	but have not shown beneficial effects on eGFR.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	but have not shown beneficial effects on eGFR.	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__noRel	but have not shown beneficial effects on eGFR.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	but have not shown beneficial effects on eGFR.	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	but have not shown beneficial effects on eGFR.	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	but have not shown beneficial effects on eGFR.
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__Support	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	but have not shown beneficial effects on eGFR.
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__Attack	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	but have not shown beneficial effects on eGFR.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	but have not shown beneficial effects on eGFR.
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__Attack	but the system is complex and not amenable to simple explanation or prior prediction.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	but have not shown beneficial effects on eGFR.
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__Attack	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).
__label__noRel	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).
__label__Support	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.
__label__noRel	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.
__label__noRel	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).
__label__noRel	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).
__label__Support	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.
__label__noRel	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.
__label__noRel	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).
__label__noRel	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).
__label__Support	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.
__label__noRel	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.
__label__noRel	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).
__label__noRel	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).
__label__noRel	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).
__label__Support	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.
__label__noRel	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.	Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).
__label__noRel	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.	The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).
__label__noRel	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.	The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).
__label__noRel	Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension.	AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.
__label__noRel	It shows that a sequential combination of interferon-α and lamivudine was beneficial.	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.
__label__noRel	It shows that a sequential combination of interferon-α and lamivudine was beneficial.	No LAM resistance emerged at week 96.
__label__noRel	It shows that a sequential combination of interferon-α and lamivudine was beneficial.	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.
__label__noRel	It shows that a sequential combination of interferon-α and lamivudine was beneficial.	For all patients, no serious adverse events were observed.
__label__noRel	It shows that a sequential combination of interferon-α and lamivudine was beneficial.	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.
__label__noRel	It shows that a sequential combination of interferon-α and lamivudine was beneficial.	It remains unresolved how children with immune-tolerant CHB should be treated.
__label__Support	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.	It shows that a sequential combination of interferon-α and lamivudine was beneficial.
__label__noRel	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.	No LAM resistance emerged at week 96.
__label__noRel	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.
__label__noRel	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.	For all patients, no serious adverse events were observed.
__label__noRel	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.
__label__noRel	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.	It remains unresolved how children with immune-tolerant CHB should be treated.
__label__Support	No LAM resistance emerged at week 96.	It shows that a sequential combination of interferon-α and lamivudine was beneficial.
__label__noRel	No LAM resistance emerged at week 96.	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.
__label__noRel	No LAM resistance emerged at week 96.	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.
__label__noRel	No LAM resistance emerged at week 96.	For all patients, no serious adverse events were observed.
__label__noRel	No LAM resistance emerged at week 96.	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.
__label__noRel	No LAM resistance emerged at week 96.	It remains unresolved how children with immune-tolerant CHB should be treated.
__label__Support	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.	It shows that a sequential combination of interferon-α and lamivudine was beneficial.
__label__noRel	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.
__label__noRel	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.	No LAM resistance emerged at week 96.
__label__noRel	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.	For all patients, no serious adverse events were observed.
__label__noRel	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.
__label__noRel	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.	It remains unresolved how children with immune-tolerant CHB should be treated.
__label__Support	For all patients, no serious adverse events were observed.	It shows that a sequential combination of interferon-α and lamivudine was beneficial.
__label__noRel	For all patients, no serious adverse events were observed.	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.
__label__noRel	For all patients, no serious adverse events were observed.	No LAM resistance emerged at week 96.
__label__noRel	For all patients, no serious adverse events were observed.	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.
__label__noRel	For all patients, no serious adverse events were observed.	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.
__label__noRel	For all patients, no serious adverse events were observed.	It remains unresolved how children with immune-tolerant CHB should be treated.
__label__Support	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.	It shows that a sequential combination of interferon-α and lamivudine was beneficial.
__label__noRel	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.
__label__noRel	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.	No LAM resistance emerged at week 96.
__label__noRel	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.
__label__noRel	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.	For all patients, no serious adverse events were observed.
__label__noRel	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.	It remains unresolved how children with immune-tolerant CHB should be treated.
__label__noRel	It remains unresolved how children with immune-tolerant CHB should be treated.	It shows that a sequential combination of interferon-α and lamivudine was beneficial.
__label__noRel	It remains unresolved how children with immune-tolerant CHB should be treated.	Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.
__label__noRel	It remains unresolved how children with immune-tolerant CHB should be treated.	No LAM resistance emerged at week 96.
__label__noRel	It remains unresolved how children with immune-tolerant CHB should be treated.	In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.
__label__noRel	It remains unresolved how children with immune-tolerant CHB should be treated.	For all patients, no serious adverse events were observed.
__label__noRel	It remains unresolved how children with immune-tolerant CHB should be treated.	Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.
__label__noRel	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
__label__noRel	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
__label__noRel	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
__label__noRel	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
__label__noRel	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
__label__Support	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
__label__noRel	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
__label__noRel	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
__label__Support	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
__label__noRel	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
__label__noRel	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
__label__noRel	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
__label__noRel	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.
__label__noRel	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.
__label__noRel	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.
__label__Support	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.
__label__noRel	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.
__label__noRel	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.
__label__noRel	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.
__label__Support	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.
__label__noRel	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.
__label__noRel	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.
__label__noRel	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.
__label__Support	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.
__label__noRel	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.
__label__noRel	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.
__label__noRel	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.
__label__Support	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.
__label__noRel	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.	In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.
__label__noRel	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.	RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.
__label__noRel	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.	Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.
__label__noRel	This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH.	RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.
__label__noRel	By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).	None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.
__label__noRel	By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).	TDF was generally well tolerated and there were no severe treatment-related adverse events.
__label__Support	By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).	In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
__label__noRel	None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.	By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).
__label__noRel	None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.	TDF was generally well tolerated and there were no severe treatment-related adverse events.
__label__noRel	None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.	In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
__label__noRel	TDF was generally well tolerated and there were no severe treatment-related adverse events.	By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).
__label__noRel	TDF was generally well tolerated and there were no severe treatment-related adverse events.	None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.
__label__noRel	TDF was generally well tolerated and there were no severe treatment-related adverse events.	In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
__label__noRel	In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.	By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).
__label__noRel	In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.	None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.
__label__noRel	In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.	TDF was generally well tolerated and there were no severe treatment-related adverse events.
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__Support	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__Support	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.	Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.
__label__Support	Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.	Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.
__label__noRel	Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.	Regular consumption of this product may be used as a potential functional food.
__label__noRel	Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.	Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.
__label__noRel	Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.	Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.
__label__noRel	Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.	Regular consumption of this product may be used as a potential functional food.
__label__noRel	Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.	Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.
__label__noRel	Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.	Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.
__label__Support	Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.	Regular consumption of this product may be used as a potential functional food.
__label__noRel	Regular consumption of this product may be used as a potential functional food.	Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 ± 12.26 mmHg vs. 124.77 ± 11.04 mmHg) and diastolic blood pressure (80.7 ± 9 vs. 84.5 ± 8.5 mmHg)] from the fermented milk group was lower than the control group.
__label__noRel	Regular consumption of this product may be used as a potential functional food.	Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.
__label__noRel	Regular consumption of this product may be used as a potential functional food.	Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.
__label__noRel	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.
__label__noRel	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.
__label__noRel	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.
__label__noRel	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.	Denileukin diftitox was not associated with any clinically significant myelosuppression.
__label__noRel	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.
__label__noRel	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.
__label__noRel	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.
__label__noRel	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.
__label__noRel	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.	Denileukin diftitox was not associated with any clinically significant myelosuppression.
__label__Support	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.
__label__noRel	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.
__label__noRel	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.
__label__noRel	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.
__label__noRel	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.	Denileukin diftitox was not associated with any clinically significant myelosuppression.
__label__Support	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.
__label__noRel	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.
__label__noRel	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.
__label__noRel	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.
__label__noRel	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.	Denileukin diftitox was not associated with any clinically significant myelosuppression.
__label__noRel	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.
__label__noRel	Denileukin diftitox was not associated with any clinically significant myelosuppression.	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.
__label__noRel	Denileukin diftitox was not associated with any clinically significant myelosuppression.	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.
__label__noRel	Denileukin diftitox was not associated with any clinically significant myelosuppression.	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.
__label__noRel	Denileukin diftitox was not associated with any clinically significant myelosuppression.	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.
__label__noRel	Denileukin diftitox was not associated with any clinically significant myelosuppression.	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.
__label__noRel	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.	Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.
__label__noRel	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.	Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.
__label__noRel	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.	Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.
__label__noRel	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.	Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.
__label__noRel	Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.	Denileukin diftitox was not associated with any clinically significant myelosuppression.
__label__noRel	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
__label__noRel	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).
__label__noRel	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).
__label__noRel	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.
__label__noRel	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
__label__noRel	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
__label__noRel	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).
__label__noRel	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).
__label__noRel	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).
__label__noRel	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.
__label__noRel	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
__label__noRel	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
__label__noRel	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).
__label__noRel	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
__label__noRel	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).
__label__noRel	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.
__label__Support	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
__label__noRel	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
__label__noRel	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).
__label__noRel	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
__label__noRel	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).
__label__noRel	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.
__label__Support	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
__label__noRel	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
__label__noRel	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).
__label__noRel	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
__label__noRel	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).
__label__noRel	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).
__label__noRel	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
__label__Support	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
__label__noRel	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).
__label__noRel	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
__label__noRel	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).
__label__noRel	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).
__label__noRel	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.
__label__noRel	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
__label__noRel	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.	Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).
__label__noRel	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.	Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
__label__noRel	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.	There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).
__label__noRel	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.	Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).
__label__noRel	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.	After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.
__label__noRel	patients who crossed over to imatinib reported higher QoL than those who remained on IFN.	Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
__label__noRel	vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.	there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).
__label__Support	vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.	This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.
__label__noRel	there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).	vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.
__label__noRel	there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).	This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.
__label__noRel	This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.	vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.
__label__noRel	This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.	there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).
__label__noRel	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,
__label__noRel	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.
__label__noRel	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).
__label__noRel	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.
__label__noRel	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).
__label__noRel	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).
__label__noRel	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.
__label__noRel	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).
__label__noRel	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.
__label__noRel	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).
__label__noRel	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).
__label__noRel	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,
__label__noRel	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).
__label__noRel	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.
__label__noRel	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).
__label__noRel	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).
__label__noRel	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,
__label__Support	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.
__label__noRel	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.
__label__noRel	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).
__label__noRel	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).
__label__noRel	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,
__label__noRel	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.
__label__noRel	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).
__label__noRel	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).
__label__noRel	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).	Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).
__label__Support	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).	significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels,
__label__noRel	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).	no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial.
__label__noRel	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).	There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P > 0.05).
__label__noRel	After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P < 0.05).	Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D.
__label__noRel	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.
__label__noRel	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.
__label__Support	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).
__label__noRel	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).	spironolactone is preferable for the fourth-drug therapy.
__label__noRel	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).
__label__noRel	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.
__label__Support	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).
__label__noRel	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.	spironolactone is preferable for the fourth-drug therapy.
__label__noRel	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).
__label__noRel	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.
__label__Support	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).
__label__noRel	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.	spironolactone is preferable for the fourth-drug therapy.
__label__noRel	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).
__label__noRel	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.
__label__noRel	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.
__label__Support	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).	spironolactone is preferable for the fourth-drug therapy.
__label__noRel	spironolactone is preferable for the fourth-drug therapy.	Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).
__label__noRel	spironolactone is preferable for the fourth-drug therapy.	Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.
__label__noRel	spironolactone is preferable for the fourth-drug therapy.	spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.
__label__noRel	spironolactone is preferable for the fourth-drug therapy.	clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (≈21%).
__label__noRel	Survival advantage was significant with regular surveillance but not with irregular surveillance.	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).
__label__noRel	Survival advantage was significant with regular surveillance but not with irregular surveillance.	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.
__label__noRel	Survival advantage was significant with regular surveillance but not with irregular surveillance.	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.
__label__noRel	Survival advantage was significant with regular surveillance but not with irregular surveillance.	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.
__label__noRel	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).	Survival advantage was significant with regular surveillance but not with irregular surveillance.
__label__noRel	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.
__label__noRel	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.
__label__Support	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.
__label__Support	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.	Survival advantage was significant with regular surveillance but not with irregular surveillance.
__label__noRel	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).
__label__noRel	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.
__label__noRel	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.
__label__Support	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.	Survival advantage was significant with regular surveillance but not with irregular surveillance.
__label__noRel	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).
__label__noRel	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.
__label__noRel	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.
__label__noRel	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.	Survival advantage was significant with regular surveillance but not with irregular surveillance.
__label__noRel	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.	Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).
__label__noRel	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.	Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.
__label__noRel	HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.	When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.
__label__noRel	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).
__label__noRel	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.
__label__Support	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),	Psychological factors impact the HRQoL of treated patients.
__label__noRel	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),	A longitudinal and qualitative study should refine these results.
__label__noRel	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),
__label__noRel	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.
__label__Support	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).	Psychological factors impact the HRQoL of treated patients.
__label__noRel	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).	A longitudinal and qualitative study should refine these results.
__label__noRel	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),
__label__noRel	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).
__label__Support	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.	Psychological factors impact the HRQoL of treated patients.
__label__noRel	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.	A longitudinal and qualitative study should refine these results.
__label__noRel	Psychological factors impact the HRQoL of treated patients.	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),
__label__noRel	Psychological factors impact the HRQoL of treated patients.	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).
__label__noRel	Psychological factors impact the HRQoL of treated patients.	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.
__label__noRel	Psychological factors impact the HRQoL of treated patients.	A longitudinal and qualitative study should refine these results.
__label__noRel	A longitudinal and qualitative study should refine these results.	Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004),
__label__noRel	A longitudinal and qualitative study should refine these results.	negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).
__label__noRel	A longitudinal and qualitative study should refine these results.	Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.
__label__Attack	A longitudinal and qualitative study should refine these results.	Psychological factors impact the HRQoL of treated patients.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__Support	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	DC resulted in a more favorable overall response and survival rate than VC.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__Support	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	DC resulted in a more favorable overall response and survival rate than VC.
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__Support	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	DC resulted in a more favorable overall response and survival rate than VC.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__Support	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	DC resulted in a more favorable overall response and survival rate than VC.
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	DC resulted in a more favorable overall response and survival rate than VC.
__label__Support	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	DC resulted in a more favorable overall response and survival rate than VC.
__label__Support	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	DC resulted in a more favorable overall response and survival rate than VC.
__label__Support	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__noRel	DC resulted in a more favorable overall response and survival rate than VC.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__Support	DC resulted in a more favorable overall response and survival rate than VC.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__noRel	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	DC resulted in a more favorable overall response and survival rate than VC.
__label__Support	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	DC resulted in a more favorable overall response and survival rate than VC.
__label__noRel	These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.	Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
__label__noRel	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.
__label__noRel	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.
__label__noRel	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.
__label__noRel	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.
__label__noRel	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.
__label__noRel	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.
__label__Support	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.
__label__noRel	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.
__label__noRel	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.
__label__noRel	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.
__label__Support	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.
__label__noRel	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.
__label__noRel	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.
__label__noRel	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.
__label__noRel	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.
__label__noRel	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.
__label__noRel	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.	iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.
__label__noRel	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.	The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.
__label__noRel	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.	The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.
__label__Support	Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.	among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__Support	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__Support	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__Support	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__Support	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	Both treatments demonstrated favorable ocular tolerability.
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	Both treatments demonstrated favorable ocular tolerability.
__label__Support	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	Both treatments demonstrated favorable ocular tolerability.
__label__Support	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	Both treatments demonstrated favorable ocular tolerability.
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.	The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p = 0.032) and transforming growth factor-β (p = 0.008), but not for type IV collagen (p = 0.174).
__label__noRel	This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.	Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.
__label__Support	The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p = 0.032) and transforming growth factor-β (p = 0.008), but not for type IV collagen (p = 0.174).	This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.
__label__noRel	The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p = 0.032) and transforming growth factor-β (p = 0.008), but not for type IV collagen (p = 0.174).	Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.
__label__Support	Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.	This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B.
__label__noRel	Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.	The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p = 0.032) and transforming growth factor-β (p = 0.008), but not for type IV collagen (p = 0.174).
__label__noRel	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).
__label__noRel	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);
__label__noRel	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.
__label__noRel	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.
__label__Support	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.
__label__noRel	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.
__label__noRel	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).
__label__noRel	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);
__label__noRel	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.
__label__Support	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.
__label__noRel	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.
__label__noRel	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.
__label__noRel	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).
__label__noRel	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).
__label__noRel	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.
__label__noRel	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.
__label__Support	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.
__label__noRel	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.
__label__noRel	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).
__label__noRel	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).
__label__noRel	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);
__label__noRel	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.
__label__Support	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.
__label__noRel	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.
__label__noRel	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).
__label__noRel	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).
__label__noRel	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);
__label__noRel	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.
__label__noRel	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.
__label__noRel	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.
__label__noRel	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).
__label__noRel	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).
__label__noRel	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);
__label__noRel	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.
__label__noRel	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.
__label__noRel	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.
__label__noRel	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.	Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).
__label__noRel	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.	Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).
__label__noRel	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.	In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039);
__label__noRel	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.	SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.
__label__noRel	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.	Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.
__label__noRel	Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS.	Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.
__label__noRel	Peak oxygen consumption increased by 0.24 L/min in the exercise group,	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).
__label__noRel	Peak oxygen consumption increased by 0.24 L/min in the exercise group,	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).
__label__noRel	Peak oxygen consumption increased by 0.24 L/min in the exercise group,	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
__label__Support	Peak oxygen consumption increased by 0.24 L/min in the exercise group,	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
__label__noRel	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).	Peak oxygen consumption increased by 0.24 L/min in the exercise group,
__label__noRel	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).
__label__noRel	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
__label__Support	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
__label__noRel	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).	Peak oxygen consumption increased by 0.24 L/min in the exercise group,
__label__noRel	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).
__label__noRel	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
__label__Support	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
__label__noRel	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).	Peak oxygen consumption increased by 0.24 L/min in the exercise group,
__label__noRel	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).
__label__noRel	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).
__label__Support	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
__label__noRel	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.	Peak oxygen consumption increased by 0.24 L/min in the exercise group,
__label__noRel	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.	whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).
__label__noRel	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.	Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).
__label__noRel	Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.	Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
__label__noRel	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.
__label__noRel	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),
__label__noRel	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
__label__noRel	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).	Adverse events were comparable between groups.
__label__Support	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
__label__noRel	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
__label__noRel	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).
__label__noRel	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),
__label__noRel	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
__label__noRel	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.	Adverse events were comparable between groups.
__label__Support	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
__label__noRel	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
__label__noRel	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).
__label__noRel	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.
__label__noRel	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
__label__noRel	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),	Adverse events were comparable between groups.
__label__noRel	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
__label__Support	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
__label__noRel	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).
__label__noRel	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.
__label__noRel	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),
__label__noRel	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.	Adverse events were comparable between groups.
__label__Support	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
__label__noRel	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
__label__noRel	Adverse events were comparable between groups.	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).
__label__noRel	Adverse events were comparable between groups.	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.
__label__noRel	Adverse events were comparable between groups.	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),
__label__noRel	Adverse events were comparable between groups.	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
__label__Support	Adverse events were comparable between groups.	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
__label__noRel	Adverse events were comparable between groups.	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
__label__noRel	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).
__label__noRel	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.
__label__noRel	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),
__label__noRel	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
__label__noRel	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.	Adverse events were comparable between groups.
__label__noRel	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
__label__noRel	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.	Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).
__label__noRel	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.	Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.
__label__noRel	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.	Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),
__label__noRel	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.	Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
__label__noRel	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.	Adverse events were comparable between groups.
__label__noRel	Encouraging results regarding increased survival warrant another trial designed to confirm these findings.	Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
__label__noRel	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__Support	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__noRel	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__noRel	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__Support	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__noRel	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__Support	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	No obvious renin angiotensin system activation was found after LSSalt intervention.	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P = .006) compared with that of the ISH NSalt group,
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P = .158) in the NISH LSSalt group compared with that of the NISH NSalt group.
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	No obvious renin angiotensin system activation was found after LSSalt intervention.
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention,
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction.
__label__noRel	Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.	Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.
__label__noRel	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.
__label__noRel	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.
__label__noRel	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;
__label__noRel	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.
__label__noRel	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).
__label__noRel	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.
__label__Support	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;
__label__noRel	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.
__label__noRel	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).
__label__noRel	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.
__label__Support	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;
__label__noRel	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.
__label__noRel	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).
__label__noRel	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.
__label__noRel	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.
__label__noRel	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.
__label__noRel	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.	Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).
__label__noRel	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.	Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.
__label__noRel	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.	At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.
__label__noRel	these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension.	The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents;
__label__noRel	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).
__label__noRel	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.
__label__noRel	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.
__label__Support	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.
__label__noRel	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).
__label__noRel	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.
__label__noRel	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.
__label__Support	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.
__label__noRel	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).
__label__noRel	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).
__label__noRel	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.
__label__Support	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.
__label__noRel	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).
__label__noRel	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).
__label__noRel	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.
__label__Support	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.
__label__noRel	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.	The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).
__label__noRel	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.	The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).
__label__noRel	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.	95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.
__label__noRel	In Peg-IFN-α regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-α-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-α-2a.	The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	Toxicities in both arms were mild.
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	No patients developed hemolytic uremic syndrome.
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	although there was no statistically significant difference in QOL between arms.
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__Support	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).	but this did not translate into a survival advantage.
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	Toxicities in both arms were mild.
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	No patients developed hemolytic uremic syndrome.
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	although there was no statistically significant difference in QOL between arms.
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__Support	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).	but this did not translate into a survival advantage.
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	Toxicities in both arms were mild.
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	No patients developed hemolytic uremic syndrome.
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	although there was no statistically significant difference in QOL between arms.
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__Support	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).	but this did not translate into a survival advantage.
__label__noRel	Toxicities in both arms were mild.	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	Toxicities in both arms were mild.	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	Toxicities in both arms were mild.	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	Toxicities in both arms were mild.	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	Toxicities in both arms were mild.	No patients developed hemolytic uremic syndrome.
__label__noRel	Toxicities in both arms were mild.	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	Toxicities in both arms were mild.	although there was no statistically significant difference in QOL between arms.
__label__noRel	Toxicities in both arms were mild.	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	Toxicities in both arms were mild.	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	Toxicities in both arms were mild.	but this did not translate into a survival advantage.
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	Toxicities in both arms were mild.
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	No patients developed hemolytic uremic syndrome.
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	although there was no statistically significant difference in QOL between arms.
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.	but this did not translate into a survival advantage.
__label__noRel	No patients developed hemolytic uremic syndrome.	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	No patients developed hemolytic uremic syndrome.	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	No patients developed hemolytic uremic syndrome.	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	No patients developed hemolytic uremic syndrome.	Toxicities in both arms were mild.
__label__noRel	No patients developed hemolytic uremic syndrome.	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	No patients developed hemolytic uremic syndrome.	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	No patients developed hemolytic uremic syndrome.	although there was no statistically significant difference in QOL between arms.
__label__noRel	No patients developed hemolytic uremic syndrome.	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	No patients developed hemolytic uremic syndrome.	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	No patients developed hemolytic uremic syndrome.	but this did not translate into a survival advantage.
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	Toxicities in both arms were mild.
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	No patients developed hemolytic uremic syndrome.
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	although there was no statistically significant difference in QOL between arms.
__label__Support	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,	but this did not translate into a survival advantage.
__label__noRel	although there was no statistically significant difference in QOL between arms.	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	although there was no statistically significant difference in QOL between arms.	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	although there was no statistically significant difference in QOL between arms.	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	although there was no statistically significant difference in QOL between arms.	Toxicities in both arms were mild.
__label__noRel	although there was no statistically significant difference in QOL between arms.	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	although there was no statistically significant difference in QOL between arms.	No patients developed hemolytic uremic syndrome.
__label__Attack	although there was no statistically significant difference in QOL between arms.	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	although there was no statistically significant difference in QOL between arms.	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	although there was no statistically significant difference in QOL between arms.	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	although there was no statistically significant difference in QOL between arms.	but this did not translate into a survival advantage.
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	Toxicities in both arms were mild.
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	No patients developed hemolytic uremic syndrome.
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	although there was no statistically significant difference in QOL between arms.
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.	but this did not translate into a survival advantage.
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	Toxicities in both arms were mild.
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	No patients developed hemolytic uremic syndrome.
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	although there was no statistically significant difference in QOL between arms.
__label__Support	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__noRel	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,	but this did not translate into a survival advantage.
__label__noRel	but this did not translate into a survival advantage.	The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
__label__noRel	but this did not translate into a survival advantage.	Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
__label__noRel	but this did not translate into a survival advantage.	Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
__label__noRel	but this did not translate into a survival advantage.	Toxicities in both arms were mild.
__label__noRel	but this did not translate into a survival advantage.	There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.
__label__noRel	but this did not translate into a survival advantage.	No patients developed hemolytic uremic syndrome.
__label__noRel	but this did not translate into a survival advantage.	Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,
__label__noRel	but this did not translate into a survival advantage.	although there was no statistically significant difference in QOL between arms.
__label__noRel	but this did not translate into a survival advantage.	These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
__label__Attack	but this did not translate into a survival advantage.	PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	The choice of insulin treatment is not influencing BTMs,
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	metformin treatment may decrease BTMs,
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	The choice of insulin treatment is not influencing BTMs,	metformin treatment may decrease BTMs,
__label__noRel	The choice of insulin treatment is not influencing BTMs,	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	metformin treatment may decrease BTMs,	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	metformin treatment may decrease BTMs,	The choice of insulin treatment is not influencing BTMs,
__label__noRel	metformin treatment may decrease BTMs,	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	metformin treatment may decrease BTMs,	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	metformin treatment may decrease BTMs,	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	metformin treatment may decrease BTMs,	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	metformin treatment may decrease BTMs,	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	metformin treatment may decrease BTMs,	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	metformin treatment may decrease BTMs,
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	metformin treatment may decrease BTMs,
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__Support	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	metformin treatment may decrease BTMs,
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	The choice of insulin treatment is not influencing BTMs,
__label__Support	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	metformin treatment may decrease BTMs,
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__Support	Allocation of insulin regimens was not associated with different levels of BTMs.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	metformin treatment may decrease BTMs,
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	metformin treatment may decrease BTMs,
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	These physical changes can negatively affect health-related quality of life.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__noRel	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	These physical changes can negatively affect health-related quality of life.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	These physical changes can negatively affect health-related quality of life.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	These physical changes can negatively affect health-related quality of life.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	These physical changes can negatively affect health-related quality of life.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	These physical changes can negatively affect health-related quality of life.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__noRel	These physical changes can negatively affect health-related quality of life.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__noRel	These physical changes can negatively affect health-related quality of life.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	These physical changes can negatively affect health-related quality of life.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__noRel	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	These physical changes can negatively affect health-related quality of life.
__label__noRel	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__Support	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__noRel	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	These physical changes can negatively affect health-related quality of life.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__noRel	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	These physical changes can negatively affect health-related quality of life.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__noRel	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	These physical changes can negatively affect health-related quality of life.
__label__noRel	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__Support	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.	This form of exercise can be an important component of supportive care for these patients.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	These physical changes can negatively affect health-related quality of life.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.
__label__noRel	This form of exercise can be an important component of supportive care for these patients.	Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
__label__Attack	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.
__label__noRel	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).
__label__noRel	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)
__label__noRel	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).
__label__Support	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.
__label__noRel	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).
__label__noRel	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).
__label__noRel	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)
__label__noRel	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).
__label__Support	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.
__label__noRel	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).
__label__noRel	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.
__label__noRel	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)
__label__noRel	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).
__label__Support	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.
__label__noRel	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).
__label__noRel	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.
__label__noRel	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).
__label__noRel	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).
__label__noRel	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.
__label__noRel	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).
__label__noRel	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.
__label__noRel	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).
__label__noRel	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)
__label__noRel	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.
__label__noRel	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.	Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001).
__label__noRel	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.	For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively.
__label__noRel	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.	Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020).
__label__noRel	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.	Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033)
__label__noRel	CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life.	indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).
__label__noRel	In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.	In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).
__label__noRel	In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.	The rate of adverse events did not differ significantly between groups.
__label__noRel	In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.	The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).
__label__Support	In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).	In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.
__label__noRel	In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).	The rate of adverse events did not differ significantly between groups.
__label__noRel	In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).	The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).
__label__noRel	The rate of adverse events did not differ significantly between groups.	In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.
__label__noRel	The rate of adverse events did not differ significantly between groups.	In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).
__label__noRel	The rate of adverse events did not differ significantly between groups.	The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).
__label__Support	The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).	In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission.
__label__noRel	The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).	In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).
__label__noRel	The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).	The rate of adverse events did not differ significantly between groups.
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__Support	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	but the differences were not statistically significant.
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__Support	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	but the differences were not statistically significant.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	but the differences were not statistically significant.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	but the differences were not statistically significant.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	but the differences were not statistically significant.
__label__noRel	but the differences were not statistically significant.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	but the differences were not statistically significant.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__Attack	but the differences were not statistically significant.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	but the differences were not statistically significant.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__noRel	but the differences were not statistically significant.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	The number of hospital admissions and the number of days in hospital were not different.
__label__Support	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.	G-CSF did not prevent serious infections.
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	The number of hospital admissions and the number of days in hospital were not different.
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).	G-CSF did not prevent serious infections.
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	The number of hospital admissions and the number of days in hospital were not different.
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.	G-CSF did not prevent serious infections.
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	The number of hospital admissions and the number of days in hospital were not different.
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).	G-CSF did not prevent serious infections.
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	The number of hospital admissions and the number of days in hospital were not different.
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.	G-CSF did not prevent serious infections.
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	The number of hospital admissions and the number of days in hospital were not different.	G-CSF did not prevent serious infections.
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	The number of hospital admissions and the number of days in hospital were not different.
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	In elderly patients, G-CSF improved the RDI of CHOP,	G-CSF did not prevent serious infections.
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	The number of hospital admissions and the number of days in hospital were not different.
__label__Attack	but this did not lead to a higher complete response rate or better overall survival.	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	but this did not lead to a higher complete response rate or better overall survival.	G-CSF did not prevent serious infections.
__label__noRel	G-CSF did not prevent serious infections.	In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.
__label__noRel	G-CSF did not prevent serious infections.	The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).
__label__noRel	G-CSF did not prevent serious infections.	The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.
__label__noRel	G-CSF did not prevent serious infections.	Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).
__label__noRel	G-CSF did not prevent serious infections.	Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.
__label__noRel	G-CSF did not prevent serious infections.	The number of hospital admissions and the number of days in hospital were not different.
__label__noRel	G-CSF did not prevent serious infections.	In elderly patients, G-CSF improved the RDI of CHOP,
__label__noRel	G-CSF did not prevent serious infections.	but this did not lead to a higher complete response rate or better overall survival.
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	the SLT's effect was significant only during the nighttime.
__label__Support	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	the SLT's effect was significant only during the nighttime.
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__Support	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	the SLT's effect was significant only during the nighttime.
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__Support	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	the SLT's effect was significant only during the nighttime.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	the SLT's effect was significant only during the nighttime.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	the SLT's effect was significant only during the nighttime.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	the SLT's effect was significant only during the nighttime.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	the SLT's effect was significant only during the nighttime.	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	the SLT's effect was significant only during the nighttime.	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	the SLT's effect was significant only during the nighttime.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	the SLT's effect was significant only during the nighttime.
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	the SLT's effect was significant only during the nighttime.
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.
__label__noRel	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.
__label__noRel	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	Safety observations were consistent with SAD findings.
__label__noRel	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.
__label__noRel	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	ZGN-1061 was well tolerated with no safety signals in all doses tested.
__label__noRel	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
__label__noRel	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.
__label__noRel	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.
__label__noRel	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.	Safety observations were consistent with SAD findings.
__label__noRel	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.
__label__Support	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.	ZGN-1061 was well tolerated with no safety signals in all doses tested.
__label__noRel	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
__label__noRel	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.
__label__noRel	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.
__label__noRel	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.	Safety observations were consistent with SAD findings.
__label__noRel	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.
__label__noRel	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.	ZGN-1061 was well tolerated with no safety signals in all doses tested.
__label__noRel	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
__label__noRel	Safety observations were consistent with SAD findings.	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.
__label__noRel	Safety observations were consistent with SAD findings.	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.
__label__noRel	Safety observations were consistent with SAD findings.	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.
__label__noRel	Safety observations were consistent with SAD findings.	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.
__label__noRel	Safety observations were consistent with SAD findings.	ZGN-1061 was well tolerated with no safety signals in all doses tested.
__label__noRel	Safety observations were consistent with SAD findings.	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
__label__noRel	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.
__label__noRel	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.
__label__noRel	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.
__label__noRel	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.	Safety observations were consistent with SAD findings.
__label__noRel	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.	ZGN-1061 was well tolerated with no safety signals in all doses tested.
__label__noRel	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
__label__noRel	ZGN-1061 was well tolerated with no safety signals in all doses tested.	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.
__label__noRel	ZGN-1061 was well tolerated with no safety signals in all doses tested.	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.
__label__noRel	ZGN-1061 was well tolerated with no safety signals in all doses tested.	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.
__label__noRel	ZGN-1061 was well tolerated with no safety signals in all doses tested.	Safety observations were consistent with SAD findings.
__label__noRel	ZGN-1061 was well tolerated with no safety signals in all doses tested.	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.
__label__noRel	ZGN-1061 was well tolerated with no safety signals in all doses tested.	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
__label__noRel	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.	Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.
__label__noRel	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.	ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.
__label__noRel	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.	All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.
__label__noRel	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.	Safety observations were consistent with SAD findings.
__label__noRel	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.	Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.
__label__noRel	the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.	ZGN-1061 was well tolerated with no safety signals in all doses tested.
__label__noRel	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.
__label__noRel	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.
__label__noRel	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.
__label__Support	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.
__label__noRel	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).	This reiterates the role of amnion as a safe and effective bleb modulator.
__label__noRel	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).
__label__noRel	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.
__label__noRel	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.
__label__Support	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.
__label__noRel	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.	This reiterates the role of amnion as a safe and effective bleb modulator.
__label__noRel	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).
__label__noRel	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.
__label__noRel	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.
__label__Support	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.
__label__noRel	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.	This reiterates the role of amnion as a safe and effective bleb modulator.
__label__noRel	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).
__label__noRel	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.
__label__noRel	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.
__label__Support	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.
__label__noRel	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.	This reiterates the role of amnion as a safe and effective bleb modulator.
__label__noRel	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).
__label__noRel	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.
__label__noRel	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.
__label__noRel	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.
__label__noRel	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.	This reiterates the role of amnion as a safe and effective bleb modulator.
__label__noRel	This reiterates the role of amnion as a safe and effective bleb modulator.	Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).
__label__noRel	This reiterates the role of amnion as a safe and effective bleb modulator.	IOP reduced by 71.1% in study group from 41.9 ± 10.6 to 12.1 ± 2.7 mmHg and from 40.5 ± 8.5 to 12.8 ± 4.5 mmHg in control group, a decline of 68.29%.
__label__noRel	This reiterates the role of amnion as a safe and effective bleb modulator.	Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.
__label__noRel	This reiterates the role of amnion as a safe and effective bleb modulator.	The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.
__label__noRel	This reiterates the role of amnion as a safe and effective bleb modulator.	Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.
__label__noRel	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.
__label__noRel	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.
__label__noRel	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.
__label__noRel	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.
__label__noRel	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.
__label__noRel	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.
__label__noRel	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.
__label__noRel	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.
__label__noRel	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.
__label__noRel	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.
__label__noRel	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.
__label__noRel	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	There were no reports of treatment-related headaches.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	There were no reports of treatment-related headaches.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	There were no reports of treatment-related headaches.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	There were no reports of treatment-related headaches.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	There were no reports of treatment-related headaches.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	There were no reports of treatment-related headaches.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	There were no reports of treatment-related headaches.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	There were no reports of treatment-related headaches.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	There were no reports of treatment-related headaches.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	There were no reports of treatment-related headaches.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	There were no reports of treatment-related headaches.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__Support	There were no reports of treatment-related headaches.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	There were no reports of treatment-related headaches.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	The number of subjects reporting adverse events and the number of adverse events did not change with dose.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	There were no reports of treatment-related headaches.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	There were no reports of treatment-related headaches.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	There were no reports of treatment-related headaches.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	There were no reports of treatment-related headaches.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	There were no reports of treatment-related headaches.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	No changes were observed in HbA1c levels or PulseOx.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	There were no reports of treatment-related headaches.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	No changes were observed in HbA1c levels or PulseOx.
__label__Support	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	There were no reports of treatment-related headaches.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	There were no reports of treatment-related headaches.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	There were no reports of treatment-related headaches.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	The number of subjects reporting adverse events and the number of adverse events did not change with dose.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	No changes were observed in HbA1c levels or PulseOx.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.
__label__noRel	Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.	The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.
__label__noRel	Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).	Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).
__label__Support	Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).	There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.
__label__noRel	Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).	Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).
__label__Support	Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).	There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.
__label__noRel	There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.	Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).
__label__noRel	There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.	Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Attack	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Support	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Support	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Support	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	Both groups had a similar favorable long-term safety profile.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	Both groups had a similar favorable long-term safety profile.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	Both groups had a similar favorable long-term safety profile.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	Both groups had a similar favorable long-term safety profile.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__noRel	Both groups had a similar favorable long-term safety profile.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__Support	The incidence of adverse events was low in both groups through 24 months of follow-up.	Both groups had a similar favorable long-term safety profile.
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	Both groups had a similar favorable long-term safety profile.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__Support	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	Both groups had a similar favorable long-term safety profile.
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__Support	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	Both groups had a similar favorable long-term safety profile.
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__Support	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	Both groups had a similar favorable long-term safety profile.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	No serious adverse reactions were observed.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__Support	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	No serious adverse reactions were observed.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__Support	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	No serious adverse reactions were observed.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	No serious adverse reactions were observed.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	No serious adverse reactions were observed.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__Support	No serious adverse reactions were observed.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	No serious adverse reactions were observed.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	No serious adverse reactions were observed.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	No serious adverse reactions were observed.
__label__Support	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	No serious adverse reactions were observed.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	No serious adverse reactions were observed.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	No serious adverse reactions were observed.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	Ocular irritation was frequently seen in DTFC group.	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	Ocular irritation was frequently seen in DTFC group.	blurred vision was frequently seen in BTFC group,
__label__noRel	Ocular irritation was frequently seen in DTFC group.	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__noRel	Ocular irritation was frequently seen in DTFC group.	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__noRel	Ocular irritation was frequently seen in DTFC group.	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	Ocular irritation was frequently seen in DTFC group.	treatment difference decreased and disappeared with time.
__label__noRel	Ocular irritation was frequently seen in DTFC group.	No noteworthy issue was observed in other safety outcome.
__label__noRel	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	Ocular irritation was frequently seen in DTFC group.
__label__noRel	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	blurred vision was frequently seen in BTFC group,
__label__Support	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__noRel	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__noRel	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	treatment difference decreased and disappeared with time.
__label__noRel	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,	No noteworthy issue was observed in other safety outcome.
__label__noRel	blurred vision was frequently seen in BTFC group,	Ocular irritation was frequently seen in DTFC group.
__label__noRel	blurred vision was frequently seen in BTFC group,	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	blurred vision was frequently seen in BTFC group,	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__Support	blurred vision was frequently seen in BTFC group,	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__noRel	blurred vision was frequently seen in BTFC group,	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	blurred vision was frequently seen in BTFC group,	treatment difference decreased and disappeared with time.
__label__noRel	blurred vision was frequently seen in BTFC group,	No noteworthy issue was observed in other safety outcome.
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	Ocular irritation was frequently seen in DTFC group.
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	blurred vision was frequently seen in BTFC group,
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	treatment difference decreased and disappeared with time.
__label__noRel	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.	No noteworthy issue was observed in other safety outcome.
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	Ocular irritation was frequently seen in DTFC group.
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	blurred vision was frequently seen in BTFC group,
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	treatment difference decreased and disappeared with time.
__label__noRel	the score of blurred vision was transiently higher in BTFC than DTFC,	No noteworthy issue was observed in other safety outcome.
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	Ocular irritation was frequently seen in DTFC group.
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	blurred vision was frequently seen in BTFC group,
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	treatment difference decreased and disappeared with time.
__label__noRel	BTFC can be considered as a safe and effective agent for glaucoma treatment.	No noteworthy issue was observed in other safety outcome.
__label__noRel	treatment difference decreased and disappeared with time.	Ocular irritation was frequently seen in DTFC group.
__label__noRel	treatment difference decreased and disappeared with time.	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	treatment difference decreased and disappeared with time.	blurred vision was frequently seen in BTFC group,
__label__noRel	treatment difference decreased and disappeared with time.	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__Attack	treatment difference decreased and disappeared with time.	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__noRel	treatment difference decreased and disappeared with time.	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	treatment difference decreased and disappeared with time.	No noteworthy issue was observed in other safety outcome.
__label__noRel	No noteworthy issue was observed in other safety outcome.	Ocular irritation was frequently seen in DTFC group.
__label__noRel	No noteworthy issue was observed in other safety outcome.	Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group,
__label__noRel	No noteworthy issue was observed in other safety outcome.	blurred vision was frequently seen in BTFC group,
__label__noRel	No noteworthy issue was observed in other safety outcome.	Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.
__label__noRel	No noteworthy issue was observed in other safety outcome.	the score of blurred vision was transiently higher in BTFC than DTFC,
__label__Support	No noteworthy issue was observed in other safety outcome.	BTFC can be considered as a safe and effective agent for glaucoma treatment.
__label__noRel	No noteworthy issue was observed in other safety outcome.	treatment difference decreased and disappeared with time.
